Further comments on “High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis”

פריטים דומים

• High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis
  מאת: Messori, Andrea, et al.
  יצא לאור: (2018)
• Haemophilia B is clinically less severe than haemophilia A: further evidence
  מאת: Franchini, Massimo, et al.
  יצא לאור: (2018)
• Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better
  מאת: Mannucci, Pier Mannuccio
  יצא לאור: (2010)
• Factor VIII inhibitor and source of replacement therapy
  מאת: Mannucci, Pier Mannuccio, et al.
  יצא לאור: (2012)
• Factor VIII replacement is still the standard of care in haemophilia A
  מאת: Aledort, Louis, et al.
  יצא לאור: (2019)